Have a personal or library account? Click to login
Cardiac fibrosis and atrial fibrillation Cover

Cardiac fibrosis and atrial fibrillation

Postępy Higieny i Medycyny Doświadczalnej
Volume 76 (2022): Issue 1 (January 2022)
By: Klaudia Katarzyna Mickiewicz,  Anna Lisowska and  Małgorzata Knapp  
Open Access
|Jul 2022

Figures & Tables

Fig. 1

Fibroblast growth factor (FGF)-23 and its effect on cardiac fibroblast activity.FGF receptor 1 (FGFR1), phospholipase C (PLC), inositol 1,4,5-trisphosphate (IP3), calcium channel protein 1 (Orai1), IP3 receptor (IP3R)
Fibroblast growth factor (FGF)-23 and its effect on cardiac fibroblast activity.FGF receptor 1 (FGFR1), phospholipase C (PLC), inositol 1,4,5-trisphosphate (IP3), calcium channel protein 1 (Orai1), IP3 receptor (IP3R)
DOI: https://doi.org/10.2478/ahem-2022-0035 | Journal eISSN: 1732-2693
Journal RSS Feed
Language: English
Page range: 307 - 314
Submitted on: Oct 28, 2021
Accepted on: Mar 28, 2022
Published on: Jul 11, 2022
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
atrial fibrillation,
cardiac fibrosis,
galectin-3,
sST2,
AGTL,
HE4,
TGF-β,
FGF-23,
PICP,
PIIINP,
CITP
Related subjects:
Life sciences,
Molecular biology,
Microbiology and virology,
Medicine,
Basic medical science,
Immunology

© 2022 Klaudia Katarzyna Mickiewicz, Anna Lisowska, Małgorzata Knapp, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 76 (2022): Issue 1 (January 2022)Next article